{"id":"deramiocel-cap-1002","safety":{"commonSideEffects":[{"rate":null,"effect":"Pericardial effusion"},{"rate":null,"effect":"Arrhythmia"},{"rate":null,"effect":"Infection at injection site"},{"rate":null,"effect":"Chest pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CAP-1002 consists of cardiosphere-derived cells (CDCs) derived from donated heart tissue that are expanded ex vivo and administered to patients with cardiac damage. These cells work through paracrine mechanisms—secreting anti-inflammatory cytokines and growth factors—to reduce fibrosis, promote angiogenesis, and preserve cardiac function. The therapy aims to regenerate damaged myocardium and prevent progressive heart failure.","oneSentence":"Deramiocel is an allogeneic cardiosphere-derived cell therapy that promotes cardiac repair and reduces inflammation following myocardial injury.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:09:03.125Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myocardial infarction with reduced ejection fraction"},{"name":"Duchenne muscular dystrophy-associated cardiomyopathy"}]},"trialDetails":[{"nctId":"NCT05126758","phase":"PHASE3","title":"A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Capricor Inc.","startDate":"2022-06-22","conditions":"Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic","enrollment":106},{"nctId":"NCT04428476","phase":"PHASE2","title":"Open-label Extension of the HOPE-2 Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Capricor Inc.","startDate":"2020-08-05","conditions":"Duchenne Muscular Dystrophy","enrollment":13},{"nctId":"NCT03406780","phase":"PHASE2","title":"A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy","status":"COMPLETED","sponsor":"Capricor Inc.","startDate":"2018-04-04","conditions":"Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Allogeneic Cardiosphere-Derived Cells","Cardiosphere-Derived Cells (CDCs)"],"phase":"phase_3","status":"active","brandName":"Deramiocel (CAP-1002)","genericName":"Deramiocel (CAP-1002)","companyName":"Capricor Inc.","companyId":"capricor-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Deramiocel is an allogeneic cardiosphere-derived cell therapy that promotes cardiac repair and reduces inflammation following myocardial injury. Used for Acute myocardial infarction with reduced ejection fraction, Duchenne muscular dystrophy-associated cardiomyopathy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}